PhytoHealth Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 0/6
PhytoHealth has been growing earnings at an average annual rate of 27.9%, while the Pharmaceuticals industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 11.6% per year.
Key information
27.9%
Earnings growth rate
32.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 18.5% |
| Revenue growth rate | 11.6% |
| Return on equity | -3.3% |
| Net Margin | -29.0% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How PhytoHealth makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 162 | -47 | 97 | 93 |
| 30 Sep 23 | 150 | -52 | 97 | 100 |
| 30 Jun 23 | 140 | -55 | 94 | 103 |
| 31 Mar 23 | 133 | -58 | 93 | 102 |
| 31 Dec 22 | 135 | -79 | 94 | 120 |
| 30 Sep 22 | 142 | -76 | 89 | 120 |
| 30 Jun 22 | 156 | -72 | 91 | 112 |
| 31 Mar 22 | 179 | -81 | 89 | 129 |
| 31 Dec 21 | 169 | -78 | 90 | 120 |
| 30 Sep 21 | 160 | -72 | 89 | 104 |
| 30 Jun 21 | 136 | -108 | 90 | 116 |
| 31 Mar 21 | 104 | -79 | 92 | 113 |
| 31 Dec 20 | 92 | -88 | 91 | 125 |
| 30 Sep 20 | 74 | -137 | 100 | 143 |
| 30 Jun 20 | 68 | -148 | 101 | 156 |
| 31 Mar 20 | 78 | -175 | 104 | 159 |
| 31 Dec 19 | 95 | -171 | 105 | 164 |
| 30 Sep 19 | 105 | -177 | 105 | 166 |
| 30 Jun 19 | 113 | -177 | 108 | 165 |
| 31 Mar 19 | 109 | -179 | 112 | 169 |
| 31 Dec 18 | 107 | -182 | 117 | 168 |
| 30 Sep 18 | 100 | -193 | 115 | 166 |
| 30 Jun 18 | 93 | -191 | 111 | 164 |
| 31 Mar 18 | 76 | -200 | 106 | 151 |
| 31 Dec 17 | 54 | -206 | 99 | 146 |
| 30 Sep 17 | 47 | -170 | 94 | 142 |
| 30 Jun 17 | 35 | -163 | 92 | 136 |
| 31 Mar 17 | 30 | -180 | 94 | 148 |
| 31 Dec 16 | 25 | -195 | 90 | 162 |
| 30 Sep 16 | 22 | -176 | 94 | 147 |
| 30 Jun 16 | 20 | -182 | 89 | 157 |
| 31 Mar 16 | 19 | -189 | 89 | 163 |
| 31 Dec 15 | 21 | -203 | 94 | 175 |
| 30 Sep 15 | 23 | -261 | 95 | 231 |
| 30 Jun 15 | 45 | -303 | 108 | 231 |
| 31 Mar 15 | 68 | -357 | 93 | 296 |
| 31 Dec 14 | 91 | -322 | 84 | 263 |
| 30 Sep 14 | 112 | -345 | 77 | 273 |
| 30 Jun 14 | 109 | -311 | 63 | 267 |
| 31 Mar 14 | 128 | -227 | 65 | 176 |
| 31 Dec 13 | 145 | -183 | 62 | 177 |
| 30 Sep 13 | 166 | -108 | 70 | 101 |
| 30 Jun 13 | 187 | -72 | 72 | 93 |
Quality Earnings: 4108 is currently unprofitable.
Growing Profit Margin: 4108 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4108 is unprofitable, but has reduced losses over the past 5 years at a rate of 27.9% per year.
Accelerating Growth: Unable to compare 4108's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4108 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-15%).
Return on Equity
High ROE: 4108 has a negative Return on Equity (-3.27%), as it is currently unprofitable.